NUCLIDIUM wins EIC Accelerator grant to further advance its CuTrace platform for personalised cancer diagnostics
The European Innovation Council (EIC) has awarded Nuclidium with its Accelerator grant of €2,5 million to develop novel, broadly available Copper-based PET tracers for the diagnosis of a broad range of cancer indications. The EIC Accelerator program focuses on high impact innovations and on creating new markets. The innovations considered for funding should be cutting-edge, and particularly focused on scientific and/or technological discoveries.
Nuclidium has won a second Innosuisse Grant of €800.000 to improve treatment of carcinomas via precision imaging of the tumour microenvironment with a novel Copper-61-based PET tracer.
Innosuisse has awarded Nuclidium with a €1 million grant to further advance its development of a proprietary platform of novel PET tracers based on Copper-61.